Targovax scores potential $100M KRAS vaccine deal in China Jan. 8, 2020 By Cormac Sheridan No Comments DUBLIN – Shares in Targovax ASA rose as much as 26% Wednesday on news of an option and license agreement in China involving its peptide-based KRAS-directed cancer vaccines, TG-01 and TG-02. Read More